Employers on the Andel marketplace set their own contribution toward Wegovy, the daily Wegovy pill and Wegovy HD, with manufacturer-direct pricing and no insurance involved.
Recap by typeshit. Full story at Yahoo Finance.
Prof Jeanne Lubbe and Discovery Health weigh in. Discovery says GLP-1 claims tripled from 2022 to 2025, with members claiming for 5.4 months on average.
A guide to employer plans, Medicare Part D's weight-loss exclusion, Medicaid and paying cash, plus how added uses like sleep apnea open coverage.
Business Day says medicines endorsed by the WHO still aren't available to public sector patients. The drugs involved aren't named in the share.
A study of 288,907 insured people found other medical costs rose about 22 cents per drug dollar. Also covers Medicare's $245 Bridge price and employer cutbacks.
Vomiting fell to 43% from 58.5% on placebo, and Vanda plans to seek an expanded approval for GLP-1 nausea based on the results.
Novo presented the post hoc look at its phase 3 trial at The Menopause Society Annual Meeting, focusing on results for women taking the combination shot.
Loading…